Business Wire

euNetworks Expands Its Long Haul Network to Warsaw and Bratislava, Delivering Three Routes Into Poland to Meet Bandwidth Demand

14.12.2021 14:25:00 EET | Business Wire | Press release

Share

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has expanded its long haul network into Poland, delivering three new routes to Warsaw. These routes deliver around 2,977km of newly lit fibre connecting Warsaw directly with Berlin and Hamburg, with the third route via Brno, supporting traffic to Prague, Bratislava and Vienna. This expansion, which took 9 months to deliver, supports euNetworks’ customers’ demand for better diversity into the region. The system is in service, carrying multiple Terabits of customer traffic on each span that will rapidly grow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005710/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

euNetworks' 3 long routes to Warsaw (Graphic: Business Wire)

The new long haul routes were designed to deliver a unique triverse topology to market. Each route lands in a separate data centre in Warsaw, with scope to further expand as new data centres come into service in the region. The north route is 924km long, extends from Berlin and Hamburg and is unique in the market. Its route diversity also enables customers to bypass Berlin should they need to. The middle route is 845km long, running from euNetworks’ Berlin data centre facility into Warsaw. The south route, at 1,178km, delivers the shortest path to market between Vienna and Warsaw and enables Bratislava in Slovakia as a new point of presence for euNetworks along the way.

These routes connect into the key data centres and data centre hubs in Warsaw. This investment supports euNetworks’ customers’ bandwidth needs in this important market as well as onwards diversity and triversity to the rest of Europe. euNetworks’ long haul network now spans 17 countries, connecting 53 cities. Combined with euNetworks’ extensive metro networks in 17 cities, the long haul network enables any data centre to any data centre connectivity between all these metros on their owned and operated fibre, end-to-end.

The expansion East follows deployment of additional critical infrastructure linking the UK and the Netherlands, with euNetworks’ latest Super Highway along with subsea cable Scylla going live in September 2021.

“Warsaw is an exciting new region for data centre growth and is an important market experiencing strong bandwidth growth,” said Paula Cogan, President, euNetworks. “It’s a growing cloud region in Europe, with its geographic position making it a key connectivity hub for hyperscalers and cloud service providers. We continue to develop our network in support of our customers’ bandwidth requirements across Europe. Our expansion into Poland enables us to continue to offer a seamless and end to end data centre connectivity experience for our customers on our network with the same service delivery and support experience they have come to value.”

euNetworks’ 100g and 400G Wavelengths, 1G and 10G Ethernet, Cloud Connect and Multi Service Port products and solutions are now available in Warsaw, with plans for additional direct connection to further data centres in the region and in Warsaw to support customers’ needs in the future.

euNetworks builds and invests in its city and long haul fibre networks to connect the key data centres and data centre hubs across Europe. The company builds Super Highways on long haul routes that are critical to Europe’s future international bandwidth needs and uses low loss fibre on these routes to deliver a low cost per bit long haul solution for its customers.

About euNetworks

euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 465 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

euNetworks contact:
Hannah Britt |
Senior Director, Marketing & IR | euNetworks
hannah.britt@eunetworks.com email
| +44 7717 896 446 mobile

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye